CN107440010A - 基于沙丁鱼活性提取物的复配物及其制备方法 - Google Patents
基于沙丁鱼活性提取物的复配物及其制备方法 Download PDFInfo
- Publication number
- CN107440010A CN107440010A CN201710480889.1A CN201710480889A CN107440010A CN 107440010 A CN107440010 A CN 107440010A CN 201710480889 A CN201710480889 A CN 201710480889A CN 107440010 A CN107440010 A CN 107440010A
- Authority
- CN
- China
- Prior art keywords
- sardine
- activity extract
- preparation
- compound
- parts
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 230000000694 effects Effects 0.000 title claims abstract description 75
- 235000019512 sardine Nutrition 0.000 title claims abstract description 58
- 239000000284 extract Substances 0.000 title claims abstract description 43
- 150000001875 compounds Chemical class 0.000 title claims abstract description 38
- 238000002360 preparation method Methods 0.000 title claims abstract description 24
- 238000000605 extraction Methods 0.000 title abstract description 8
- 241001125046 Sardina pilchardus Species 0.000 title 1
- 241001125048 Sardina Species 0.000 claims abstract description 58
- 102000004190 Enzymes Human genes 0.000 claims abstract description 18
- 108090000790 Enzymes Proteins 0.000 claims abstract description 18
- 229920001661 Chitosan Polymers 0.000 claims abstract description 8
- 239000000648 calcium alginate Substances 0.000 claims abstract description 8
- 235000010410 calcium alginate Nutrition 0.000 claims abstract description 8
- 229960002681 calcium alginate Drugs 0.000 claims abstract description 8
- OKHHGHGGPDJQHR-YMOPUZKJSA-L calcium;(2s,3s,4s,5s,6r)-6-[(2r,3s,4r,5s,6r)-2-carboxy-6-[(2r,3s,4r,5s,6r)-2-carboxylato-4,5,6-trihydroxyoxan-3-yl]oxy-4,5-dihydroxyoxan-3-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylate Chemical compound [Ca+2].O[C@@H]1[C@H](O)[C@H](O)O[C@@H](C([O-])=O)[C@H]1O[C@H]1[C@@H](O)[C@@H](O)[C@H](O[C@H]2[C@H]([C@@H](O)[C@H](O)[C@H](O2)C([O-])=O)O)[C@H](C(O)=O)O1 OKHHGHGGPDJQHR-YMOPUZKJSA-L 0.000 claims abstract description 8
- 239000000737 potassium alginate Substances 0.000 claims abstract description 6
- 235000010408 potassium alginate Nutrition 0.000 claims abstract description 6
- MZYRDLHIWXQJCQ-YZOKENDUSA-L potassium alginate Chemical compound [K+].[K+].O1[C@@H](C([O-])=O)[C@@H](OC)[C@H](O)[C@H](O)[C@@H]1O[C@@H]1[C@@H](C([O-])=O)O[C@@H](O)[C@@H](O)[C@H]1O MZYRDLHIWXQJCQ-YZOKENDUSA-L 0.000 claims abstract description 6
- 229940088594 vitamin Drugs 0.000 claims abstract description 6
- 239000011782 vitamin Substances 0.000 claims abstract description 6
- 229930003231 vitamin Natural products 0.000 claims abstract description 6
- 235000013343 vitamin Nutrition 0.000 claims abstract description 6
- 150000003722 vitamin derivatives Chemical class 0.000 claims abstract description 6
- 239000000203 mixture Substances 0.000 claims abstract description 5
- 239000002994 raw material Substances 0.000 claims abstract description 5
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 13
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 12
- 108091005804 Peptidases Proteins 0.000 claims description 9
- 239000004365 Protease Substances 0.000 claims description 9
- 102100037486 Reverse transcriptase/ribonuclease H Human genes 0.000 claims description 6
- 239000003513 alkali Substances 0.000 claims description 6
- 230000009849 deactivation Effects 0.000 claims description 6
- 239000007788 liquid Substances 0.000 claims description 6
- 238000005119 centrifugation Methods 0.000 claims description 5
- 238000001471 micro-filtration Methods 0.000 claims description 5
- 235000019362 perlite Nutrition 0.000 claims description 5
- 238000000108 ultra-filtration Methods 0.000 claims description 5
- 210000000988 bone and bone Anatomy 0.000 claims description 4
- 239000000919 ceramic Substances 0.000 claims description 4
- 230000002401 inhibitory effect Effects 0.000 claims description 4
- 239000012528 membrane Substances 0.000 claims description 4
- 210000001835 viscera Anatomy 0.000 claims description 4
- 238000004140 cleaning Methods 0.000 claims description 3
- 238000004108 freeze drying Methods 0.000 claims description 3
- 238000011017 operating method Methods 0.000 claims description 2
- 239000010451 perlite Substances 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 1
- 230000007935 neutral effect Effects 0.000 claims 1
- 108010021724 tonin Proteins 0.000 claims 1
- 102100030988 Angiotensin-converting enzyme Human genes 0.000 abstract description 17
- 230000001077 hypotensive effect Effects 0.000 abstract description 17
- 208000001953 Hypotension Diseases 0.000 abstract description 16
- 208000021822 hypotensive Diseases 0.000 abstract description 16
- 101800000733 Angiotensin-2 Proteins 0.000 abstract description 13
- 229950006323 angiotensin ii Drugs 0.000 abstract description 13
- 101800004538 Bradykinin Proteins 0.000 abstract description 12
- 102400000967 Bradykinin Human genes 0.000 abstract description 12
- QXZGBUJJYSLZLT-UHFFFAOYSA-N H-Arg-Pro-Pro-Gly-Phe-Ser-Pro-Phe-Arg-OH Natural products NC(N)=NCCCC(N)C(=O)N1CCCC1C(=O)N1C(C(=O)NCC(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CO)C(=O)N2C(CCC2)C(=O)NC(CC=2C=CC=CC=2)C(=O)NC(CCCN=C(N)N)C(O)=O)CCC1 QXZGBUJJYSLZLT-UHFFFAOYSA-N 0.000 abstract description 12
- QXZGBUJJYSLZLT-FDISYFBBSA-N bradykinin Chemical compound NC(=N)NCCC[C@H](N)C(=O)N1CCC[C@H]1C(=O)N1[C@H](C(=O)NCC(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CO)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)CCC1 QXZGBUJJYSLZLT-FDISYFBBSA-N 0.000 abstract description 12
- 102400000344 Angiotensin-1 Human genes 0.000 abstract description 10
- 101800000734 Angiotensin-1 Proteins 0.000 abstract description 10
- ORWYRWWVDCYOMK-HBZPZAIKSA-N angiotensin I Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC(C)C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 ORWYRWWVDCYOMK-HBZPZAIKSA-N 0.000 abstract description 10
- 230000007062 hydrolysis Effects 0.000 abstract description 10
- 238000006460 hydrolysis reaction Methods 0.000 abstract description 10
- 235000019658 bitter taste Nutrition 0.000 abstract description 4
- 238000011161 development Methods 0.000 abstract description 3
- 231100000331 toxic Toxicity 0.000 abstract description 3
- 230000002588 toxic effect Effects 0.000 abstract description 3
- 239000002932 luster Substances 0.000 abstract description 2
- 102000005862 Angiotensin II Human genes 0.000 abstract 1
- CZGUSIXMZVURDU-JZXHSEFVSA-N Ile(5)-angiotensin II Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CC=1C=CC=CC=1)C([O-])=O)NC(=O)[C@@H](NC(=O)[C@H](CCCNC(N)=[NH2+])NC(=O)[C@@H]([NH3+])CC([O-])=O)C(C)C)C1=CC=C(O)C=C1 CZGUSIXMZVURDU-JZXHSEFVSA-N 0.000 abstract 1
- 230000009286 beneficial effect Effects 0.000 abstract 1
- 239000008280 blood Substances 0.000 description 14
- 210000004369 blood Anatomy 0.000 description 14
- 229940088598 enzyme Drugs 0.000 description 13
- CUKWUWBLQQDQAC-VEQWQPCFSA-N (3s)-3-amino-4-[[(2s)-1-[[(2s)-1-[[(2s)-1-[[(2s,3s)-1-[[(2s)-1-[(2s)-2-[[(1s)-1-carboxyethyl]carbamoyl]pyrrolidin-1-yl]-3-(1h-imidazol-5-yl)-1-oxopropan-2-yl]amino]-3-methyl-1-oxopentan-2-yl]amino]-3-(4-hydroxyphenyl)-1-oxopropan-2-yl]amino]-3-methyl-1-ox Chemical compound C([C@@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C)C(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C1=CC=C(O)C=C1 CUKWUWBLQQDQAC-VEQWQPCFSA-N 0.000 description 12
- 102400000345 Angiotensin-2 Human genes 0.000 description 12
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 12
- 230000036772 blood pressure Effects 0.000 description 11
- 210000004204 blood vessel Anatomy 0.000 description 9
- 238000000034 method Methods 0.000 description 9
- 235000019688 fish Nutrition 0.000 description 8
- 241000251468 Actinopterygii Species 0.000 description 7
- 235000012000 cholesterol Nutrition 0.000 description 6
- 235000013305 food Nutrition 0.000 description 6
- 230000004060 metabolic process Effects 0.000 description 6
- 230000002792 vascular Effects 0.000 description 6
- 230000004531 blood pressure lowering effect Effects 0.000 description 5
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 5
- 241000555825 Clupeidae Species 0.000 description 4
- 230000002255 enzymatic effect Effects 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- UUUHXMGGBIUAPW-UHFFFAOYSA-N 1-[1-[2-[[5-amino-2-[[1-[5-(diaminomethylideneamino)-2-[[1-[3-(1h-indol-3-yl)-2-[(5-oxopyrrolidine-2-carbonyl)amino]propanoyl]pyrrolidine-2-carbonyl]amino]pentanoyl]pyrrolidine-2-carbonyl]amino]-5-oxopentanoyl]amino]-3-methylpentanoyl]pyrrolidine-2-carbon Chemical compound C1CCC(C(=O)N2C(CCC2)C(O)=O)N1C(=O)C(C(C)CC)NC(=O)C(CCC(N)=O)NC(=O)C1CCCN1C(=O)C(CCCN=C(N)N)NC(=O)C1CCCN1C(=O)C(CC=1C2=CC=CC=C2NC=1)NC(=O)C1CCC(=O)N1 UUUHXMGGBIUAPW-UHFFFAOYSA-N 0.000 description 3
- 101000984728 Chiropsoides quadrigatus Angiotensin-converting enzyme inhibitory peptide Proteins 0.000 description 3
- 102000035195 Peptidases Human genes 0.000 description 3
- 102000007079 Peptide Fragments Human genes 0.000 description 3
- 108010033276 Peptide Fragments Proteins 0.000 description 3
- 108090000882 Peptidyl-Dipeptidase A Proteins 0.000 description 3
- 206010047139 Vasoconstriction Diseases 0.000 description 3
- 150000001413 amino acids Chemical group 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 229940045110 chitosan Drugs 0.000 description 3
- 238000013329 compounding Methods 0.000 description 3
- 230000007423 decrease Effects 0.000 description 3
- 239000008187 granular material Substances 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 229920002521 macromolecule Polymers 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 238000012545 processing Methods 0.000 description 3
- 231100000419 toxicity Toxicity 0.000 description 3
- 230000001988 toxicity Effects 0.000 description 3
- 230000025033 vasoconstriction Effects 0.000 description 3
- 241000252203 Clupea harengus Species 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 241001135941 Sardinops sagax Species 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 239000000783 alginic acid Substances 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229960001126 alginic acid Drugs 0.000 description 2
- 150000004781 alginic acids Chemical class 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- 235000019514 herring Nutrition 0.000 description 2
- 235000013372 meat Nutrition 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- DECCMEWNXSNSDO-ZLUOBGJFSA-N Ala-Cys-Ala Chemical compound C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C)C(O)=O DECCMEWNXSNSDO-ZLUOBGJFSA-N 0.000 description 1
- SPIPSJXLZVTXJL-ZLUOBGJFSA-N Asn-Cys-Ser Chemical compound NC(=O)C[C@H](N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CO)C(O)=O SPIPSJXLZVTXJL-ZLUOBGJFSA-N 0.000 description 1
- 208000035404 Autolysis Diseases 0.000 description 1
- 206010057248 Cell death Diseases 0.000 description 1
- 241000251556 Chordata Species 0.000 description 1
- 241000251464 Coelacanthiformes Species 0.000 description 1
- 235000007926 Craterellus fallax Nutrition 0.000 description 1
- XGIAHEUULGOZHH-GUBZILKMSA-N Cys-Arg-Val Chemical compound CC(C)[C@@H](C(=O)O)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CS)N XGIAHEUULGOZHH-GUBZILKMSA-N 0.000 description 1
- ABLJDBFJPUWQQB-DCAQKATOSA-N Cys-Leu-Arg Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)NC(=O)[C@H](CS)N ABLJDBFJPUWQQB-DCAQKATOSA-N 0.000 description 1
- 240000007175 Datura inoxia Species 0.000 description 1
- 108010028690 Fish Proteins Proteins 0.000 description 1
- 235000019733 Fish meal Nutrition 0.000 description 1
- PYUCNHJQQVSPGN-BQBZGAKWSA-N Gly-Arg-Cys Chemical compound C(C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)CN)CN=C(N)N PYUCNHJQQVSPGN-BQBZGAKWSA-N 0.000 description 1
- NGBGZCUWFVVJKC-IRXDYDNUSA-N Gly-Tyr-Tyr Chemical compound C([C@H](NC(=O)CN)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)C1=CC=C(O)C=C1 NGBGZCUWFVVJKC-IRXDYDNUSA-N 0.000 description 1
- QCBYAHHNOHBXIH-UWVGGRQHSA-N His-Pro-Gly Chemical compound C([C@H](N)C(=O)N1[C@@H](CCC1)C(=O)NCC(O)=O)C1=CN=CN1 QCBYAHHNOHBXIH-UWVGGRQHSA-N 0.000 description 1
- DGLAHESNTJWGDO-SRVKXCTJSA-N His-Ser-His Chemical compound C1=C(NC=N1)C[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC2=CN=CN2)C(=O)O)N DGLAHESNTJWGDO-SRVKXCTJSA-N 0.000 description 1
- 206010022489 Insulin Resistance Diseases 0.000 description 1
- PINHPJWGVBKQII-SRVKXCTJSA-N Lys-Leu-Cys Chemical compound CC(C)C[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CCCCN)N PINHPJWGVBKQII-SRVKXCTJSA-N 0.000 description 1
- 102100024295 Maltase-glucoamylase Human genes 0.000 description 1
- 108090000526 Papain Proteins 0.000 description 1
- 241000384121 Sardinella Species 0.000 description 1
- QBUWQRKEHJXTOP-DCAQKATOSA-N Ser-His-Arg Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O QBUWQRKEHJXTOP-DCAQKATOSA-N 0.000 description 1
- VVKVHAOOUGNDPJ-SRVKXCTJSA-N Ser-Tyr-Ser Chemical compound [H]N[C@@H](CO)C(=O)N[C@@H](CC1=CC=C(O)C=C1)C(=O)N[C@@H](CO)C(O)=O VVKVHAOOUGNDPJ-SRVKXCTJSA-N 0.000 description 1
- SGZVZUCRAVSPKQ-FXQIFTODSA-N Ser-Val-Cys Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)O)NC(=O)[C@H](CO)N SGZVZUCRAVSPKQ-FXQIFTODSA-N 0.000 description 1
- KLGFILUOTCBNLJ-IHRRRGAJSA-N Tyr-Cys-Arg Chemical compound C1=CC(=CC=C1C[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCN=C(N)N)C(=O)O)N)O KLGFILUOTCBNLJ-IHRRRGAJSA-N 0.000 description 1
- XJFXZQKJQGYFMM-GUBZILKMSA-N Val-Cys-Val Chemical compound CC(C)[C@@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)O)N XJFXZQKJQGYFMM-GUBZILKMSA-N 0.000 description 1
- 210000001015 abdomen Anatomy 0.000 description 1
- 108010028144 alpha-Glucosidases Proteins 0.000 description 1
- 230000002929 anti-fatigue Effects 0.000 description 1
- 230000003276 anti-hypertensive effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 238000013475 authorization Methods 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 108010016616 cysteinylglycine Proteins 0.000 description 1
- 108010069495 cysteinyltyrosine Proteins 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003337 fertilizer Substances 0.000 description 1
- 235000013332 fish product Nutrition 0.000 description 1
- 239000004467 fishmeal Substances 0.000 description 1
- 238000007710 freezing Methods 0.000 description 1
- 238000005227 gel permeation chromatography Methods 0.000 description 1
- 108010015792 glycyllysine Proteins 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 108010040030 histidinoalanine Proteins 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 210000002050 maxilla Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000877 morphologic effect Effects 0.000 description 1
- 230000000050 nutritive effect Effects 0.000 description 1
- 230000001850 reproductive effect Effects 0.000 description 1
- 230000028043 self proteolysis Effects 0.000 description 1
- 239000011265 semifinished product Substances 0.000 description 1
- 239000002002 slurry Substances 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
- 239000002699 waste material Substances 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L17/00—Food-from-the-sea products; Fish products; Fish meal; Fish-egg substitutes; Preparation or treatment thereof
- A23L17/20—Fish extracts
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/17—Amino acids, peptides or proteins
- A23L33/18—Peptides; Protein hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
- A23L5/20—Removal of unwanted matter, e.g. deodorisation or detoxification
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Polymers & Plastics (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Mycology (AREA)
- Marine Sciences & Fisheries (AREA)
- Zoology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
本发明公开了基于沙丁鱼活性提取物的复配物及其制备方法,复配物的成分及其重量份为:沙丁鱼活性提取物8~13份、海藻酸钾20~30份、海藻酸钙30~40份、几丁聚糖5~10份、维生素0.5~1.3份,复配物的制备方法包括:原料预处理、双酶酶解、脱色脱苦、复配物制备。有益效果为:本发明复配物可抑制体内ACE的活性,抑制血管紧张素I向血管紧张素II转化及阻碍缓激肽的水解,达到降血压的效果;该制备方法制得沙丁鱼活性提取物纯度高,安全性高、无毒副作用,色泽较好,无苦味;制备方法简单可行,复配物产品稳定好,可设计成全自动化操作,具有较大的市场发展潜力。
Description
技术领域
本发明涉及鱼类产品深加工技术领域,尤其是涉及基于沙丁鱼活性提取物的复配物及其制备方法。
背景技术
沙丁鱼,又称沙甸鱼、萨丁鱼、鳁和鰯,它属于脊索动物门、硬骨鱼纲、鯡形目、鯡科中的沙丁鱼属、小沙丁鱼属和拟沙丁鱼属及鲱科某些食用鱼类的统称,其基本的形态特点是:小者长二寸,大者长尺许,下颚较上颚略长,齿不显,背苍腹白。我国东南部沿海有着丰富的沙丁鱼资源,其中主要的是拟沙丁鱼属中的远东拟沙丁鱼(Sardina melamosticta)。这种沙丁鱼适应广东地区的气候,主要以浮游生物、硅藻等为食,是广东地区重要的海洋经济鱼类之一,其生长快、繁殖力强、价值低。但由于其肉质嫩、脂肪含量高、酶活性强,鱼捕捞上来后,鱼肉很快会出现自溶作用,加快了鱼体的腐败过程,这也为其加工与利用带来困难。目前,在沙丁鱼加工利用方面国内仅有少量的文献报道,大多加工鱼粉、饵料和肥料,仅有小部分用于鲜销和加工成其它食品,这对资源是一种很大的浪费。
沙丁鱼的蛋白质含量较为丰富,是一种优质蛋白质资源,其生长快、产量大、价格低、营养价值高、生物活性强等特点,决定了沙丁鱼具有很大的开发价值和应用前景。沙丁鱼蛋白或肽具有多种生物学活性,包括抑制 ACE、抗氧化、抗疲劳、提高免疫、降血脂、抗凝血、抑制α-葡萄糖苷酶、治疗胰岛素抵抗和提高记忆等。利用合适的制备、分离纯化等技术方法对低值沙丁鱼进行开发,提高其附加值和利用率,对充分利用鱼类资源和大健康产业具有重要意义。
现有技术如授权公告号为CN 104031967 B的中国发明专利,公开了一种沙丁鱼降血压肽及其制备方法与应用,主要技术步骤如下:沙丁鱼预处理成均浆后,先加入木瓜蛋白酶进行酶解,再加入碱性蛋白酶进行酶解;酶解完成后灭酶,并对灭酶后的酶解液进行离心;取离心后的上清液,利用超滤、凝胶层析的方法,对粗制品进行分离纯化;对分离纯化后的高效组分进行冷冻干燥,得到沙丁鱼降血压肽。该技术通过酶解获得的沙丁鱼降血压肽,不存在安全性问题,没有化学降血压类药物的副作用,降压效果理想,但该制备方法所得的降血压肽有苦味,限制其应用。
发明内容
本发明的目的在于提供一种降血压效果好,产品纯度高,安全性高、无毒副作用,无苦味的基于沙丁鱼活性提取物的复配物及其制备方法。
本发明针对上述技术中提到的问题,采取的技术方案为:基于沙丁鱼活性提取物的复配物,成分及其重量份为:沙丁鱼活性提取物8~13份、海藻酸钾20~30份、海藻酸钙30~40份、几丁聚糖5~10份、维生素0.5~1.3份。上述复配物具有优异的降血压效果,不仅可抑制体内ACE的活性,抑制血管紧张素I 向血管紧张素II转化及阻碍缓激肽的水解,达到降血压的效果,还可加快血管壁新陈代谢,增加血管弹性,强化微血管强度与韧性,降低血液中甘油三脂和胆固醇,使血液流畅,有效降血压。
基于沙丁鱼活性提取物的复配物的制备方法,具体操作步骤为:
原料预处理:新鲜的沙丁鱼去头、内脏、骨头,清洗,加水打浆,沙丁鱼和水的重量比为20~30:1;
双酶酶解:调pH至9.5~10.5,加入1500~1700U/g碱性蛋白酶和1200~1300U/g胰蛋白酶,在50~60℃酶解2~3h,灭酶,双酶酶解法提取沙丁鱼的活性物主要是通过蛋白酶的不同作用点将蛋白大分子酶切成具有活性的肽段,该法反应条件温和、专一性强、副产物少、容易控制,能够获得高活性的提取物,且酶解后提取物的活性成分无毒无副作用;
脱色脱苦:将酶解液中加入1~1.6wt%珍珠岩,在30~40℃下脱色、脱苦55~65min,离心,经40~60nm陶瓷膜微滤,3k~8kDa截留分子量的超滤膜超滤,冷冻干燥,即得沙丁鱼活性提取物,该活性提取物中含有一种血管紧张素转化酶(ACE)抑制肽,其氨基酸序列为HSHACASYSSVCGYYVSHRGRCYCRCLRCRVLHPGKLCVCVNCSR,该肽可抑制体内ACE的活性,一方面可以抑制血管紧张素I 向血管紧张素II转化,血管紧张素II能使血管紧缩、血压升高,另一方面可以阻碍缓激肽的水解,使缓激肽保持原有的血管扩张、降血压的活性,最终达到血压下降的效果,且ACE抑制肽只对高血压患者有效,对正常人无任何副作用;
复配物制备:按配方称取沙丁鱼活性提取物、海藻酸钾、海藻酸钙、几丁聚糖、维生素,制成粉状或颗粒状食品,以温开水溶解后即可食用,该复配物具有优异的降血压效果,不仅可抑制体内ACE的活性,抑制血管紧张素I 向血管紧张素II转化及阻碍缓激肽的水解,达到降血压的效果,还可加快血管壁新陈代谢,增加血管弹性,强化微血管强度与韧性,降低血液中甘油三脂和胆固醇,使血液流畅,有效降血压。
与现有技术相比,本发明的优点在于:1)本发明复配物可抑制体内ACE的活性,抑制血管紧张素I 向血管紧张素II转化及阻碍缓激肽的水解,达到降血压的效果;2)该复配物还可加快血管壁新陈代谢,增加血管弹性,强化微血管强度与韧性,降低血液中甘油三脂和胆固醇,使血液流畅,有效降血压;3)该制备方法结合双酶酶解与脱色脱苦,使得沙丁鱼活性提取物纯度高,安全性高、无毒副作用,色泽较好,无苦味;4)制备方法简单可行,复配物产品稳定好,可设计成全自动化操作,具有较大的市场发展潜力。
具体实施方式
下面通过实施例对本发明方案作进一步说明:
实施例1 :
基于沙丁鱼活性提取物的复配物,成分及其重量份为:沙丁鱼活性提取物10份、海藻酸钾25份、海藻酸钙38份、几丁聚糖8份、维生素1份。
基于沙丁鱼活性提取物的复配物的制备方法,具体操作步骤为:
1)原料预处理:新鲜的沙丁鱼去头、内脏、骨头,用流水清洗,将沙丁鱼肉切成小块状,加水放入高速搅拌机中打浆,沙丁鱼和水的重量比为24:1;
2)双酶酶解:将鱼浆调pH至9.8,加入1700U/g碱性蛋白酶和1200U/g胰蛋白酶,在恒温50~60℃水浴中酶解2.5h,酶解过程中保持pH至9.8,酶解结束后在100℃下灭酶15min,即得酶解液,双酶酶解法提取沙丁鱼的活性物主要是通过蛋白酶的不同作用点将蛋白大分子酶切成具有活性的肽段,该法反应条件温和、专一性强、副产物少、容易控制,能够获得高活性的提取物,且酶解后提取物的活性成分无毒无副作用;
3)脱色脱苦:将酶解液中加入1.2wt%珍珠岩,在35℃下脱色、脱苦60min,然后在4000r/m、3℃的低温高速离心机内离心12min,取上清液经40nm陶瓷膜微滤,最后经7kDa截留分子量的超滤膜超滤,在真空度为0.07MPa、温度为-5℃的条件下冷冻干燥12h,即得沙丁鱼活性提取物,该活性提取物中含有一种血管紧张素转化酶(ACE)抑制肽,其氨基酸序列为HSHACASYSSVCGYYVSHRGRCYCRCLRCRVLHPGKLCVCVNCSR,该肽可抑制体内ACE的活性,一方面可以抑制血管紧张素I 向血管紧张素II转化,血管紧张素II能使血管紧缩、血压升高,另一方面可以阻碍缓激肽的水解,使缓激肽保持原有的血管扩张、降血压的活性,最终达到血压下降的效果,且ACE抑制肽只对高血压患者有效,对正常人无任何副作用;
4)复配物制备:按配方称取沙丁鱼活性提取物、海藻酸钾、海藻酸钙、几丁聚糖、维生素,混合均匀,制成粉状或颗粒状食品,以温开水溶解后即可食用,该复配物具有优异的降血压效果,不仅可抑制体内ACE的活性,抑制血管紧张素I 向血管紧张素II转化及阻碍缓激肽的水解,达到降血压的效果,还可加快血管壁新陈代谢,增加血管弹性,强化微血管强度与韧性,降低血液中甘油三脂和胆固醇,使血液流畅,有效降血压。
实施例2:
基于沙丁鱼活性提取物的复配物,成分及其重量份为:沙丁鱼活性提取物11份、海藻酸钾27份、海藻酸钙33份、几丁聚糖9份、维生素0.9份。上述复配物具有优异的降血压效果,不仅可抑制体内ACE的活性,抑制血管紧张素I 向血管紧张素II转化及阻碍缓激肽的水解,达到降血压的效果,还可加快血管壁新陈代谢,增加血管弹性,强化微血管强度与韧性,降低血液中甘油三脂和胆固醇,使血液流畅,有效降血压。
基于沙丁鱼活性提取物的复配物的制备方法,具体操作步骤为:
1)原料预处理:新鲜的远东拟沙丁鱼去头、内脏、骨头,清洗,加水打浆,沙丁鱼和水的重量比为27:1;
2)双酶酶解:调pH至10,加入1600U/g碱性蛋白酶和1300U/g胰蛋白酶,在53℃酶解3h,灭酶,双酶酶解法提取沙丁鱼的活性物主要是通过蛋白酶的不同作用点将蛋白大分子酶切成具有活性的肽段,该法反应条件温和、专一性强、副产物少、容易控制,能够获得高活性的提取物,且酶解后提取物的活性成分无毒无副作用;
3)脱色脱苦:将酶解液中加入1.5wt%珍珠岩,在40℃下脱色、脱苦65min,离心,经60nm陶瓷膜微滤,3kDa截留分子量的超滤膜超滤,冷冻干燥,即得沙丁鱼活性提取物,该活性提取物中含有一种血管紧张素转化酶(ACE)抑制肽,其氨基酸序列为HSHACASYSSVCGYYVSHRGRCYCRCLRCRVLHPGKLCVCVNCSR,该肽可抑制体内ACE的活性,一方面可以抑制血管紧张素I 向血管紧张素II转化,血管紧张素II能使血管紧缩、血压升高,另一方面可以阻碍缓激肽的水解,使缓激肽保持原有的血管扩张、降血压的活性,最终达到血压下降的效果,且ACE抑制肽只对高血压患者有效,对正常人无任何副作用;
4)复配物制备:按配方称取沙丁鱼活性提取物、海藻酸钾、海藻酸钙、几丁聚糖、维生素,制成粉状或颗粒状食品,以温开水溶解后即可食用,该复配物具有优异的降血压效果,不仅可抑制体内ACE的活性,抑制血管紧张素I 向血管紧张素II转化及阻碍缓激肽的水解,达到降血压的效果,还可加快血管壁新陈代谢,增加血管弹性,强化微血管强度与韧性,降低血液中甘油三脂和胆固醇,使血液流畅,有效降血压。
本发明的操作步骤中的常规操作为本领域技术人员所熟知,在此不进行赘述。
以上所述的实施例对本发明的技术方案进行了详细说明,应理解的是以上所述仅为本发明的具体实施例,并不用于限制本发明,凡在本发明的原则范围内所做的任何修改、补充或类似方式替代等,均应包含在本发明的保护范围之内。
SEQUENCE LISTING
<110> 新昌县南翔食品科技有限公司
<120> 基于沙丁鱼活性提取物的复配物及其制备方法
<130> 1
<160> 1
<170> PatentIn version 3.5
<210> 1
<211> 45
<212> PRT
<213> 人工合成
<400> 1
His Ser His Ala Cys Ala Ser Tyr Ser Ser Val Cys Gly Tyr Tyr Val
1 5 10 15
Ser His Arg Gly Arg Cys Tyr Cys Arg Cys Leu Arg Cys Arg Val Leu
20 25 30
His Pro Gly Lys Leu Cys Val Cys Val Asn Cys Ser Arg
35 40 45
Claims (10)
1.基于沙丁鱼活性提取物的复配物,其特征在于:所述的复配物的成分及其重量份为:沙丁鱼活性提取物8~13份、海藻酸钾20~30份、海藻酸钙30~40份、几丁聚糖5~10份、维生素0.5~1.3份。
2.根据权利要求1所述的基于沙丁鱼活性提取物的复配物,其特征在于:所述的复配物为粉状或颗粒状。
3.根据权利要求1所述的基于沙丁鱼活性提取物的复配物,其特征在于:所述的沙丁鱼活性提取物中含有一种血管紧张素转化酶抑制肽,其氨基酸序列为HSHACASYSSVCGYYVSHRGRCYCRCLRCRVLHPGKLCVCVNCSR。
4.基于沙丁鱼活性提取物的复配物的制备方法,其特征在于:所述的制备方法的具体操作步骤为:
1)原料预处理:新鲜的沙丁鱼去头、内脏、骨头,清洗,加水打浆;
2)双酶酶解:加入碱性蛋白酶和胰蛋白酶,酶解,灭酶;
3)脱色脱苦:将酶解液中加入珍珠岩,脱色脱苦,离心,微滤,超滤,冷冻干燥;
4)复配物制备。
5.根据权利要求4所述的基于沙丁鱼活性提取物的复配物的制备方法,其特征在于:所述的原料预处理步骤中沙丁鱼和水的重量比为20~30:1。
6.根据权利要求4所述的基于沙丁鱼活性提取物的复配物的制备方法,其特征在于:所述的双酶酶解步骤中碱性蛋白酶的添加量为1500~1700U/g,胰蛋白酶的添加量为1200~1300U/g。
7.根据权利要求4所述的基于沙丁鱼活性提取物的复配物的制备方法,其特征在于:所述的双酶酶解步骤中酶解pH为9.5~10.5,温度为50~60℃,时间为2~3h。
8.根据权利要求4所述的基于沙丁鱼活性提取物的复配物的制备方法,其特征在于:所述的脱色脱苦步骤中珍珠岩的添加量为1~1.6wt%,脱色脱苦温度为30~40℃,时间为55~65min。
9.根据权利要求4所述的基于沙丁鱼活性提取物的复配物的制备方法,其特征在于:所述的脱色脱苦步骤中微滤的陶瓷膜为40~60nm。
10.根据权利要求4所述的基于沙丁鱼活性提取物的复配物的制备方法,其特征在于:所述的脱色脱苦步骤中超滤膜的截留分子量3k~8kDa。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710480889.1A CN107440010A (zh) | 2017-06-22 | 2017-06-22 | 基于沙丁鱼活性提取物的复配物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710480889.1A CN107440010A (zh) | 2017-06-22 | 2017-06-22 | 基于沙丁鱼活性提取物的复配物及其制备方法 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN107440010A true CN107440010A (zh) | 2017-12-08 |
Family
ID=60486583
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710480889.1A Pending CN107440010A (zh) | 2017-06-22 | 2017-06-22 | 基于沙丁鱼活性提取物的复配物及其制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN107440010A (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114736946A (zh) * | 2022-06-10 | 2022-07-12 | 广东海洋大学 | 兼具抗疲劳与降尿酸的海洋鱼类低聚肽的制备方法及应用 |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102077934A (zh) * | 2010-09-20 | 2011-06-01 | 王强 | 一种高血压患者专用的海洋特膳食品 |
CN102251003A (zh) * | 2011-06-28 | 2011-11-23 | 国家海洋局第三海洋研究所 | 海洋生物源降压肽的制备工艺 |
CN104031967A (zh) * | 2014-06-17 | 2014-09-10 | 暨南大学 | 一种沙丁鱼降血压肽及其制备方法与应用 |
CN105420327A (zh) * | 2015-12-29 | 2016-03-23 | 广西钦州市绿源天然食品加工有限公司 | 一种提取沙丁鱼多肽的方法 |
-
2017
- 2017-06-22 CN CN201710480889.1A patent/CN107440010A/zh active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102077934A (zh) * | 2010-09-20 | 2011-06-01 | 王强 | 一种高血压患者专用的海洋特膳食品 |
CN102251003A (zh) * | 2011-06-28 | 2011-11-23 | 国家海洋局第三海洋研究所 | 海洋生物源降压肽的制备工艺 |
CN104031967A (zh) * | 2014-06-17 | 2014-09-10 | 暨南大学 | 一种沙丁鱼降血压肽及其制备方法与应用 |
CN105420327A (zh) * | 2015-12-29 | 2016-03-23 | 广西钦州市绿源天然食品加工有限公司 | 一种提取沙丁鱼多肽的方法 |
Non-Patent Citations (2)
Title |
---|
王晶晶等: ""远东拟沙丁鱼酶解产物的降血压效果评价及其ACE抑制肽的分离纯化与鉴定"", 《食品与发酵工业》 * |
车云波: "《功能食品加工技术》", 31 January 2013, 中国质检出版社 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN114736946A (zh) * | 2022-06-10 | 2022-07-12 | 广东海洋大学 | 兼具抗疲劳与降尿酸的海洋鱼类低聚肽的制备方法及应用 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN102379410B (zh) | 利用贝类及其副产品制备营养型调味品的方法 | |
US11129400B2 (en) | Method of ecological utilization of silver carp | |
CN106754151A (zh) | 肽酒的制备方法 | |
CN104357522A (zh) | 一种利用大鲵的蜕皮提取胶原蛋白的方法 | |
CN103859368A (zh) | 一种海参饮品及其生产方法 | |
CN106359839A (zh) | 一种牡蛎肽的提取方法 | |
CN113512108B (zh) | 海洋鱼皮胶原低聚肽及其制备方法和应用 | |
CN107523602A (zh) | 一种乌鸡活性肽的提取方法 | |
CN107484984B (zh) | 一种富含海参活性多糖的刺参口服液及其制造方法 | |
CN110698540B (zh) | 乌鳢蛋白来源的ace抑制肽及其制备方法 | |
CN113151385A (zh) | 一种高效制备畜禽软骨胶原蛋白多肽的方法 | |
CN107440010A (zh) | 基于沙丁鱼活性提取物的复配物及其制备方法 | |
CN1185960C (zh) | 小肽骨泥的制作方法 | |
US7297512B2 (en) | Method for producing amino acid components by enzymatic hydrolysis of fish egg skin | |
CN103740793A (zh) | 一种生产鱼皮胶原蛋白的方法 | |
KR20100033643A (ko) | 미백화된 오징어 콜라겐 유래 펩타이드의 제조방법 | |
CN111587972A (zh) | 一种牡蛎功能饮料及其生产方法 | |
CN105002250A (zh) | 一种利用鸭骨制备降血压肽的方法 | |
CN107348519A (zh) | 基于金枪鱼活性提取物的复配物及其制备方法 | |
CN102273633A (zh) | 一种牡蛎肽口服液的制造方法 | |
CN109576331A (zh) | 一种小麦胚芽肽的提取方法 | |
Vázquez et al. | Tailor-made process to recover high added value compounds from fishery by-products | |
CN107319401A (zh) | 鳕鱼活性提取物的制备方法 | |
CN113999884A (zh) | 一种甲鱼生物活性肽的制备方法 | |
CN109722462B (zh) | 一种海蜇降血脂肽及其制备方法 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
RJ01 | Rejection of invention patent application after publication |
Application publication date: 20171208 |
|
RJ01 | Rejection of invention patent application after publication |